This study suggests that ACPA status may not fully capture the biological heterogeneity between ACPA– and ACPA+ RA subgroups, indicating additional immune and metabolic distinctions that warrant further investigation. This evidence concerns the gene PRTN3 and rheumatoid arthritis.